Jackson Park Capital LLC acquired a new position in Nabriva Therapeutics AG (NASDAQ:NBRV) during the second quarter, Holdings Channel reports. The firm acquired 26,000 shares of the company’s stock, valued at approximately $195,000.
Separately, Vivo Capital LLC acquired a new position in Nabriva Therapeutics AG during the first quarter worth approximately $28,239,000. Institutional investors and hedge funds own 63.05% of the company’s stock.
Nabriva Therapeutics AG (NASDAQ:NBRV) traded down 0.70% during midday trading on Friday, reaching $7.11. The company’s stock had a trading volume of 7,507 shares. The firm’s market cap is $151.14 million. The firm has a 50 day moving average price of $7.51 and a 200-day moving average price of $7.93. Nabriva Therapeutics AG has a 52 week low of $6.61 and a 52 week high of $10.69.
Nabriva Therapeutics AG (NASDAQ:NBRV) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.50) EPS for the quarter, topping the Zacks’ consensus estimate of ($6.25) by $5.75. On average, analysts forecast that Nabriva Therapeutics AG will post ($1.93) earnings per share for the current fiscal year.
Several brokerages recently issued reports on NBRV. Zacks Investment Research lowered Nabriva Therapeutics AG from a “buy” rating to a “hold” rating in a research note on Wednesday, June 29th. Wedbush restated an “outperform” rating and set a $17.00 price target on shares of Nabriva Therapeutics AG in a research note on Tuesday, August 9th. Finally, HC Wainwright began coverage on Nabriva Therapeutics AG in a research note on Thursday, September 8th. They set a “buy” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Nabriva Therapeutics AG presently has an average rating of “Buy” and a consensus target price of $15.89.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).